Search clinical trials for: PF-06882961

Total 1296 results

Pfizer

Completed

PF-04634817 Renal Impairment Study

Renal Insufficiency

United States
Pfizer

Terminated

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

Renal Impairment | Type 2 Diabetes

United States
Telavant, Inc.
Pfizer

Completed

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

Colitis, Ulcerative

United States, Korea, Republic of, Belgium, Italy, Netherlands, Poland
Pfizer

Completed

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Severe Hemophilia

China
Pfizer

Completed

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NSCLC | SCCHN | Part 1 | MELANOMA | OVCA | SARCOMA | OTHER SOLID TUMORS | Part 1 and 2 | UROTHELIAL CARCINOMA

United States, Korea, Republic of, Russian Federation, Poland, Malaysia, Bulgaria, Ukraine
Pfizer

Completed

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Healthy Participants

China
Pfizer

Completed

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Head and Neck Neoplasms

Canada
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
National Institute on Alcohol Abuse and Alcoholism...
National Center for Advancing Translational Sciences (NCATS); University of...

Completed

A Novel Compound for Alcoholism Treatment

Alcohol Drinking | Alcohol Dependence | Alcoholism | Alcohol-Related Disorders | Alcohol Drinking Related Problems

United States
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
Pfizer

Terminated

A Study Of PF-06647263 In Patients With Advanced Solid Tumors

Neoplasms | Triple-Negative Breast Cancer

United States
Pfizer

Terminated

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Neoplasms | Breast Cancer

United States
Pfizer

Completed

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Neoplasms

United States, Netherlands
Pfizer

Completed

A Study To Understand How The Body Reacts To A Low Dose Of PF-06427878 When Given In A Vein To Healthy, Adult, Males

Healthy

United Kingdom
Verastem, Inc.

Completed

A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies (B0761001)

Cancer

United States, Canada
Pfizer

Completed

Asian Phase I Study Of PF-03446962

Neoplasms

Japan, Korea, Republic of
Pfizer

Withdrawn

A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors
Yonsei University

Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Head Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell Metastatic

Korea, Republic of
Pfizer

Completed

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

HEPATITIS C (HCV)

United States
Ablynx

Completed

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects (FIH)

Healthy

United States
Pfizer

Terminated

A Study of PF-04217903 in Patients With Advanced Cancer

Neoplasms

United States
Pfizer

Completed

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

Neoplasms

Korea, Republic of, Australia, United States
Pfizer

Completed

A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated

Healthy

Belgium
Pfizer

Completed

A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers

Pain

Belgium
Pfizer

Completed

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Neoplasms

Japan
Pfizer

Terminated

Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers

Healthy Volunteers

Singapore
Pfizer

Completed

A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Diabetes Mellitus, Type 2

Belgium
Pfizer

Not yet recruiting

A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS

Healthy Participants
Thomas Lund
Pfizer

Not yet recruiting

Self-administration of Subcutaneous Elranatamab in the Patients' Homes. (ERICA)

Multiple Myeloma
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Massachusetts General Hospital

Recruiting

Paresthesia Free Spinal Cord Stimulation (PF-SCS)

Chronic Pain | SCS

United States
University of Milano Bicocca
Pfizer

Recruiting

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)

Anaplastic Large Cell Lymphoma, ALK-Positive

Italy
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
Pfizer

Active, not recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Spain, Belgium, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, France, Italy, United Kingdom, Russian Federation, Israel, Switzerland
Pfizer

Completed

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Healthy

United States
Pfizer

Completed

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

Healthy Participants

United States
Maastricht University Medical Center
Pfizer

Completed

Ketohexokinase Inhibition in Hereditary Fructose Intolerance (KHKi in HFI)

HFI

Netherlands
Pfizer

Completed

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Healthy | Sickle Cell Anemia

United States
Pfizer

Completed

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Healthy

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Cannabis Dependence

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Healthy

Belgium
Pfizer

Terminated

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Australia, Canada, United Kingdom, Japan, Bulgaria, Italy, Poland
University of Zurich
Pfizer

Completed

Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals

Decision Making

Switzerland
Pfizer

Completed

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

Healthy

Belgium
Pfizer

Completed

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Healthy

United States
Biogen

Completed

First-in-Human Study of PF-04958242 in Healthy Volunteers

Healthy Volunteer

Singapore
Pfizer

Terminated

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

Asthma

United States
Pfizer

Completed

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Healthy Subjects

United States, Belgium
Pfizer

Completed

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Non-alcoholic Fatty Liver Disease

United States

3

Subscribe